Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 15/20 | 1.00 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881897 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL29496311 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL29577183 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL30292040 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL1326698 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL24217771 | 0.91 | CFTR (0.83) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1882597 | 0.91 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL1882593 | 0.91 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL1882595 | 0.91 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL1880600 | 0.90 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280514-A1 | METHODS OF TREATING BILE ACID DIARRHEA | UNIV CALIFORNIA (US) | 2022-09-08 | — | — | US | claimed |
| CN-113384704-B | Application of CFTR-Dvl 2-beta-catenin pathway inhibitor in leukemia and product | 四川大学华西第二医院 | 2022-05-03 | — | — | CN | claimed |
| EP-3982972-A1 | METHODS OF TREATING BILE ACID DIARRHEA | The Regents of the University of California (US) | 2022-04-20 | — | — | EP | claimed |
| US-20220088026-A1 | METHODS OF TREATING TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-03-24 | — | — | US | claimed |
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | claimed |
| EP-2866835-A1 | GPBP-1 INHIBITION AND ITS THERAPEUTIC USE | Fibrostatin, S.L. (ES) | 2015-05-06 | — | — | EP | claimed |
| WO-2014006020-A1 | GPBP-1 INHIBITION AND ITS THERAPEUTIC USE | FIBROSTATIN, S.L. (ES) | 2014-01-09 | — | — | WO | claimed |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | UNIVERSITAT DE VALENCIA (ES) | 2014-01-02 | — | — | US | claimed |
| WO-2009079373-A2 | INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-25 | — | — | WO | claimed |
| US-7235573-B2 | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | claimed |
| EP-1549321-A4 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1549321-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | claimed |
| WO-2004028480-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040063695-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-04-01 | — | — | US | claimed |
| WO-2026106983-A1 | SYNERGISTIC NHEJ INHIBITION TO OBTAIN ENRICHMENT FREE SEQUENTIAL INSERTION OF GENES > 4 KB | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125686-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF CFTR | CYSTIC FIBROSIS FOUND (US) | 2026-05-07 | — | — | US | disclosed |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | disclosed |
| WO-2004028480-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040063695-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088026-A1 | METHODS OF TREATING TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA | CFTR, LCK, ABL1 | CFTR 1/4885NLRP3 2575/4885MEN1 3449/4885 |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | CFTR, TMEM205, TMEM33 | CFTR 1/4885NLRP3 444/4885MEN1 4413/4885 |
| US-20220280514-A1 | METHODS OF TREATING BILE ACID DIARRHEA | SLC10A2, CFTR, SLC26A4 | CFTR 2/4885NLRP3 1901/4885MEN1 4452/4885 |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | CFTR 530/4885NLRP3 4283/4885MEN1 4339/4885 |
| US-20040063695-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | CFTR, TMEM205, TMEM33 | CFTR 1/4885NLRP3 444/4885MEN1 4413/4885 |
| US-20260125686-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF CFTR | CFTR, UPF1, RNGTT | CFTR 1/4885NLRP3 1294/4885MEN1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.